Category: Federal Forum Posters
Purpose: Tyrosine kinase inhibitors (TKIs) are at the forefront of oncologic medications which have changed the approach to cancer therapies previously dominated by parenteral administration. Oral formulations increase convenience for patients and have paved its way into outpatient settings. However, many oral TKIs depend on gastric pH for solubility and bioavailability. GAS therapy affects the acidic environments of the gastrointestinal tract which may adversely impact the efficacy of TKIs resulting in the possible progression of disease and treatment failure. The primary objective of this study is to determine the impact of GAS and concurrent use of TKIs on disease progression.
Methods: This study is a retrospective review comparing 2 cohorts: (1) patients with concomitant GAS therapy and TKI use (2) patients without concomitant GAS therapy and TKI use. Chart review will be conducted using the computerized patient records system (CPRS) and will include patients who received an oral TKI prescribed from Captain James A. Lovell Federal Health Care Center (FHCC) between January 1, 2010 to December 31, 2018. The following data will be collected: age, gender, weight, date of cancer diagnosis, cancer type, TKI, progression of disease, time to progression of disease, medication class of GAS therapy, and adverse reactions. Patients will be included if they are 18 years and older, veteran, and are on TKI therapy. Patients will be excluded if they had less than 10 days of TKI therapy or who were initiated with combination chemotherapy that included a TKI.
The primary outcome will be analyzed with a Chi-Square test, but based on the number of patients, a Fisher’s Exact test may be used instead. A p-value of <0.05 will be considered statistically significant.
Results: not applicable
Conclusion: not applicable
Benjamin Hung– PGY1 Pharmacy Resident, Captain James A. Lovell Federal Health Care Center, Waukegan, IL